<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id><journal-title>World Journal of Surgical Oncology</journal-title><issn pub-type="epub">1477-7819</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15606922</article-id><article-id pub-id-type="pmc">PMC546224</article-id><article-id pub-id-type="publisher-id">1477-7819-2-47</article-id><article-id pub-id-type="doi">10.1186/1477-7819-2-47</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Cheng</surname><given-names>Xi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cheng_xi1@hotmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Cai</surname><given-names>Shumo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cheng_xi1@hotmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Li</surname><given-names>Ziting</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cheng_xi1@hotmail.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tang</surname><given-names>Meiqin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cheng_xi1@hotmail.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Xue</surname><given-names>Muquan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cheng_xi1@hotmail.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Zang</surname><given-names>Rongyu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ryzang@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Gynecologic Oncology, Cancer Hospital, Fudan University, Shanghai, 200032, P.R. China</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2004</year></pub-date><volume>2</volume><fpage>47</fpage><lpage>47</lpage><ext-link ext-link-type="uri" xlink:href="http://www.wjso.com/content/2/1/47"/><history><date date-type="received"><day>1</day><month>10</month><year>2004</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Cheng et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Cheng et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Cheng
               Xi
               
               cheng_xi1@hotmail.com
            </dc:author><dc:title>
            The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>World Journal of Surgical Oncology 2(1): 47-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7819(2004)2:1&#x0003c;47&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7819</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Pelvic lymph nodes metastasis is an important prognostic factor for patients with cervical carcinoma. However, the relationships between the number of positive nodes, site of metastases nodes, adjuvant therapy and the prognosis is controversial. The purpose of this study was to investigate the influence of positive lymph nodes on the prognosis of Chinese women with stage IB1-IIB cervical carcinoma.</p></sec><sec sec-type="methods"><title>Patients and methods</title><p>Between January 1992 and December 1997, 398 women with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIB cervical carcinoma underwent radical surgery in Cancer Hospital, Fudan University. Of these sixty-six patients (16.6%) who were histologically confirmed to have positive pelvic lymph nodes were analyzed retrospectively. The survival was estimated using Kaplan-Meier method. The differences in survival were compared with Log-rank test. Multivariate analyses were performed with the Cox proportional hazard model.</p></sec><sec><title>Results</title><p>The 5-year survival of the patients with pelvic lymph nodes metastases was 40.7%. Cox proportional hazard model analysis showed that cellular differentiation, the number of positive nodes and adjuvant therapy to be the independent prognostic factors (<italic>P </italic>&#x0003c; 0.05). The 5-year survival of patients with one positive node was higher than that of those with two or more positive nodes (56.5% vs. 36.4%, <italic>P </italic>&#x0003c; 0.05). The distant metastasis rate in the former group (5.9%) was lower than the latter's (32.7%) (<italic>P </italic>= 0.05). However, there was no significant difference of pelvic recurrence between the two groups (<italic>P </italic>&#x0003e; 0.05). The number of positive nodes positively correlated with the level of positive nodes (<italic>P </italic>&#x0003c; 0.01). The 5-year survival of the patients who had no adjuvant therapy (12.6%) was much lower than that (53.7%) of those with adjuvant therapy (<italic>P </italic>&#x0003c; 0.05). However, there was no obvious difference between adjuvant radiotherapy, chemotherapy and chemo-radiotherapy (<italic>P </italic>&#x0003e; 0.05).</p></sec><sec><title>Conclusions</title><p>The prognosis of patients with stage IB1-IIB node-positive cervical carcinoma who underwent radical surgery alone was very poor. Adjuvant therapy increases the survival rate, decreases the pelvic recurrence and distant metastasis.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Although radical radiotherapy (RT) and radical surgery can be the proper choices for patients with early stage cervical cancer, most of the patients in China prefer the radical surgery to RT. Hence, in China the radical surgery has been widely used as first-line therapy for this group of women. Some poor prognostic subgroups have been identified, among these the pelvic lymph node status has been considered as the most important prognostic factor. Radical hysterectomy with bilateral pelvic lymphadenectomy produces an expected 85&#x02013;90% survival in women with stage IB and IIA cervical carcinoma without lymphatic spread. However, once tumors involve regional lymph nodes, 5-year survival has been reported to be only 30&#x02013;60% [<xref ref-type="bibr" rid="B1">1</xref>]. In most of the studies the presence of pelvic lymph node metastases has been associated with increased pelvic recurrence and distance metastases, and a decrease in overall survival [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. However, many questions such as the relationship between the numbers, the site of positive nodes, the modality of postoperative multidisciplinary therapy and the prognosis is not yet clear. This study investigated the factors that could predict the prognosis of the patients with stage IB1-IIB node-positive cervical carcinoma.</p></sec><sec sec-type="methods"><title>Patients and methods</title><p>Between January 1992 and December 1997, 398 women with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIB cervical carcinoma underwent radical surgery at the Department of Gynecologic Oncology, Cancer Hospital of Fudan University. Of these 66 patients who had undergone Wertheims-Meigs' surgery (radical hysterectomy and pelvic lymphadenectomy) and were histologically confirmed to harbor positive pelvic lymph node were included in this study. The median age at diagnosis was 49 years (range 21 to71). Out of 66, 8 patients were in stage IB1 (12.1%), 37 patients (56.1%) in stage IIA and 21 patients (31.8%) in stage IIB. Histologically 41 women (62.1%) had squamous carcinoma, 20 (30.3%) had adenocarcinoma, 4 (6.1%) adenosquamous carcinoma and 1 patient (1.5%) had small cell carcinoma. The tumors in 4 patients (6.1%) were well differentiation, 46 cases (69.7%) moderately differentiated and 16 (24.2%) poorly differentiated. The average lymph nodes resected were 14.8 per patient while the average positive lymph nodes resected were 3.7 (1~28) per patient. The average diameter of the cervical tumors was 3.6 cm (1~7 cm). The details of the patients' clinical characteristics are listed in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinico-pathologic characteristics of patients with node-positive cervical carcinoma after radical surgery</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Factors</bold></td><td align="center"><bold>n</bold></td><td align="center"><bold>Percentage (%)</bold></td></tr></thead><tbody><tr><td align="left">Age(yrs)</td><td></td><td></td></tr><tr><td align="center">&#x0003c;40</td><td align="center">15</td><td align="center">22.7</td></tr><tr><td align="center">&#x02265;40</td><td align="center">51</td><td align="center">77.3</td></tr><tr><td align="left">Stage</td><td></td><td></td></tr><tr><td align="center">IB</td><td align="center">8</td><td align="center">12.1</td></tr><tr><td align="center">IIA</td><td align="center">37</td><td align="center">56.1</td></tr><tr><td align="center">IIB</td><td align="center">21</td><td align="center">31.8</td></tr><tr><td align="left">Tumor size(cm)</td><td></td><td></td></tr><tr><td align="center">&#x0003c;4</td><td align="center">31</td><td align="center">47.0</td></tr><tr><td align="center">&#x02265;4</td><td align="center">35</td><td align="center">53.0</td></tr><tr><td align="left">Histology</td><td></td><td></td></tr><tr><td align="center">Squamous</td><td align="center">41</td><td align="center">62.1</td></tr><tr><td align="center">Adenocarcinoma</td><td align="center">20</td><td align="center">30.3</td></tr><tr><td align="center">Adenosquamous</td><td align="center">4</td><td align="center">6.1</td></tr><tr><td align="center">Others</td><td align="center">1</td><td align="center">1.5</td></tr><tr><td align="left">Differentiation</td><td></td><td></td></tr><tr><td align="center">Poor</td><td align="center">16</td><td align="center">24.2</td></tr><tr><td align="center">Moderate</td><td align="center">46</td><td align="center">69.7</td></tr><tr><td align="center">Well</td><td align="center">4</td><td align="center">6.1</td></tr><tr><td align="left">Pelvic lymph node metastases</td><td></td><td></td></tr><tr><td align="center">1</td><td align="center">17</td><td align="center">25.8</td></tr><tr><td align="center">&#x02265;2</td><td align="center">49</td><td align="center">74.2</td></tr><tr><td align="left">Parametrial extension</td><td></td><td></td></tr><tr><td align="center">Negative</td><td align="center">58</td><td align="center">87.9</td></tr><tr><td align="center">Positive</td><td align="center">8</td><td align="center">12.1</td></tr><tr><td align="left">Vaginal margin involved</td><td></td><td></td></tr><tr><td align="center">Negative</td><td align="center">64</td><td align="center">97.0</td></tr><tr><td align="center">Positive</td><td align="center">2</td><td align="center">3.0</td></tr><tr><td align="left">Depth of stromal invasion</td><td></td><td></td></tr><tr><td align="center">&#x02264;2/3</td><td align="center">19</td><td align="center">28.8</td></tr><tr><td align="center">&#x02264;2/3</td><td align="center">47</td><td align="center">71.2</td></tr><tr><td align="left">Lymphvascular permeation</td><td></td><td></td></tr><tr><td align="center">Negative</td><td align="center">47</td><td align="center">71.2</td></tr><tr><td align="center">Positive</td><td align="center">19</td><td align="center">28.8</td></tr></tbody></table></table-wrap><p>Sixty four of these women (97.0%) had brachytherapy in either three or four fractions with a total dose of 15~20 Gy at point A, two weeks prior to radical surgery because of bulky tumor or vaginal vault involvement. Intra-arterial chemotherapy was administered to 11 patients (16.7%) before surgery because of bulky tumor or parametrial extension. The regimen based on cisplatin (CDDP) + 5-Fluorouracil(5-FU) with 2~3 cycles at 3-weeks intervals was used. All patients underwent Wertheims-Meigs' procedure that included radical hysterectomy and bilateral pelvic lymphadenectomy. Three patients had para-aortic lymph node (PALN) sampling because there was suspicion of metastasis.</p><p>Postoperative external beam irradiation was delivered to 18 patients (27.3%) with 6 MV X-ray routine anterior and posterior portal at a dose of 35~45 Gy at point B with 1.8 Gy daily fraction. Two patients with positive vaginal margin were given extra brachytherapy with 15 Gy 0.5 cm below the vaginal mucosa. 12 cases with positive common iliac node and 3 with PALN metastasis received an additional 40 Gy to the PALN chain area. 10 patients (15.2%) were given postoperative chemotherapy. The regimen consisted CDDP + 5-FU + Cyclophosphamide (CTX) for squamous carcinoma, and CDDP + 5-FU + Mitomycin (MMC) for adenocarcinoma with 2~6 cycles at 3~4-weeks intervals. A total of 19 patients (28.8%) received adjuvant radiotherapy and chemotherapy as mentioned above.</p><sec><title>Follow-up</title><p>Patients were evaluated every two months for the first two years and then six monthly for the additional years by clinical interview, or telephone, or letters. Disease-free survival (DFS) was defined as the time from the date of surgery to local or nodal recurrence or metastasis. Overall survival (OS) was calculated from the date of surgery to the date of death. Recurrences were defined as local if they were detected in the pelvis or vagina and distant metastases as detected in extra-pelvic locations. The median follow-up time was 32 months (range 2~108 months).</p></sec><sec><title>Statistical analysis</title><p>Data analysis was performed with Statistical package for social sciences (SPSS) version 10.0 statistical package. The survival was calculated by Kaplan-Meier method. The differences in survival were compared with Log-rank test. Multivariate analyses were performed with the Cox proportional hazard model. The correlation analysis was performed by Kendall's method. Pearson's chi-square or Fisher's exact test was used to compare the difference of proportions. A probability value of <italic>P </italic>&#x0003c; 0.05 was considered significant.</p></sec></sec><sec><title>Results</title><p>The 5-year overall survival of the patients with pelvic lymph node metastasis was 40.7%. The 5-year survival of patients with one positive node (56.5%) was higher than that (36.4%) of those with two or more positive nodes (<italic>P </italic>&#x0003c; 0.05). The former's distant metastasis rate (5.9%) was lower than the latter's (32.7%) (<italic>P </italic>= 0.05). However, there was no significant difference of pelvic recurrence between them (<italic>P </italic>&#x0003e; 0.05) (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F1">1</xref>)</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Relationship between the number of positive nodes and prognosis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Number of positive nodes</bold></td><td align="center"><bold>n</bold></td><td align="center"><bold>5-year survival (%)</bold></td><td align="center"><bold><italic>P</italic></bold></td><td align="center"><bold>Recurrence rate (%)</bold></td><td align="center"><bold><italic>P</italic></bold></td><td align="center"><bold>Metastasis rate (%)</bold></td><td align="center"><bold><italic>P</italic></bold></td></tr></thead><tbody><tr><td align="center">1</td><td align="center">17</td><td align="center">56.5</td><td align="center">0.033</td><td align="center">23.5</td><td align="center">0.807</td><td align="center">5.9</td><td align="center">0.050</td></tr><tr><td align="center">&#x02265;2</td><td align="center">49</td><td align="center">36.4</td><td></td><td align="center">26.5</td><td></td><td align="center">32.7</td><td></td></tr></tbody></table></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p>Overall survival according to one vs. two or more positive lymph nodes.</p></caption><graphic xlink:href="1477-7819-2-47-1"/></fig><p>The 5-year survival (33.3%) of the patients with positive common iliac node and paraaortic lymph node (PALN) was less than that (43.1%) of   patients with lower than common iliac node involvement. However, the difference was not significant (P &#x0003e; 0.05). The former's pelvic recurrence rate (13.3%) was lower than the latter's (29.4%) (P &#x0003e; 0.05). However, the patients with common iliac or paraaortic nodes had significantly higher distant metastasis (53.3%) than that of the patients with lower nodes (17.6%) (P &#x0003c; 0.01). The number of the positive lymph nodes was closely correlated with the level of lymph node metastasis. The relative coefficient was 0.557 (P &#x0003c; 0.01) (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Relationship between the site of positive nodes and prognosis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Site</bold></td><td align="center"><bold>n</bold></td><td align="center"><bold>5-year survival rate (%)</bold></td><td align="center"><bold>P</bold></td><td align="center"><bold>Recurrence rate (%)</bold></td><td align="center"><bold>P</bold></td><td align="center"><bold>Metastasis rate (%)</bold></td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td align="center">Common iliac or above</td><td align="center">15</td><td align="center">33.3</td><td align="center">0.086</td><td align="center">13.3</td><td align="center">0.318</td><td align="center">53.3</td><td align="center">0.005</td></tr><tr><td align="center">Lower than common iliac</td><td align="center">51</td><td align="center">43.1</td><td></td><td align="center">29.4</td><td></td><td align="center">17.6</td><td></td></tr></tbody></table></table-wrap><p>The 5-year survival (12.6%) of the   patients who had no adjuvant therapy was much lower than that (53.7%) of   those with adjuvant therapy (P&#x0003c;0.05). The 5-year survival rates of the adjuvant radiotherapy, adjuvant chemotherapy, and adjuvant radio-chemotherapy groups were 53.5%, 49.2% and 56.1% respectively (P &#x0003e; 0.05). The pelvic recurrence (42.1%) and distant metastasis (31.6%) of the surgery alone were higher than those with adjuvant therapeutic groups. However, the differences were not significant (P &#x0003e; 0.05) (Table <xref ref-type="table" rid="T4">4</xref>, Figure <xref ref-type="fig" rid="F2">2</xref>)</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Relationship between adjuvant therapy and prognosis</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>n</bold></td><td align="center"><bold>5-year survival (%)</bold></td><td align="center"><bold>Recurrence rate (%)</bold></td><td align="center"><bold>Metastasis rate (%)</bold></td></tr></thead><tbody><tr><td align="left">No adjuvant therapy</td><td align="center">19</td><td align="center">12.6</td><td align="center">42.1</td><td align="center">31.6</td></tr><tr><td align="left">Radiotherapy</td><td align="center">18</td><td align="center">53.5</td><td align="center">22.2</td><td align="center">22.2</td></tr><tr><td align="left">Chemotherapy</td><td align="center">10</td><td align="center">49.2</td><td align="center">20.0</td><td align="center">10.0</td></tr><tr><td align="left">Radiochemotherapy</td><td align="center">19</td><td align="center">56.1</td><td align="center">15.8</td><td align="center">21.1</td></tr></tbody></table></table-wrap><fig position="float" id="F2"><label>Figure 2</label><caption><p>Overall survival according to adjuvant therapy [radiotherapy (RT) vs. chemotherapy (CT) vs. radiochemotherapy (RT+CT) vs. no adjuvant therapy (No)].</p></caption><graphic xlink:href="1477-7819-2-47-2"/></fig><sec><title>Multivariate analysis of prognostic factors</title><p>Cox proportional hazard model analysis showed that cellular differentiation, number of positive nodes and adjuvant therapy to be the independent prognostic factors for survival (<italic>P </italic>&#x0003c; 0.05) (Table <xref ref-type="table" rid="T5">5</xref>)</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Cox proportional hazard model analysis of variables in predicting overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Factors</td><td align="center">Coefficient</td><td align="center">RR</td><td align="center">95%CI</td><td align="center">P</td></tr></thead><tbody><tr><td align="left">Age</td><td align="center">-0.031</td><td align="center">0.970</td><td align="center">0.932~1.010</td><td align="left">0.136</td></tr><tr><td align="left">Stage</td><td align="center">0.283</td><td align="center">1.327</td><td align="center">0.379~4.644</td><td align="left">0.658</td></tr><tr><td align="left">Tumor size</td><td align="center">0.332</td><td align="center">1.394</td><td align="center">0.984~1.975</td><td align="left">0.061</td></tr><tr><td align="left">Histology</td><td align="center">-0.035</td><td align="center">0.966</td><td align="center">0.563~1.659</td><td align="left">0.900</td></tr><tr><td align="left">Differentiation</td><td align="center">0.787</td><td align="center">2.196</td><td align="center">1.104~4.370</td><td align="left">0.025*</td></tr><tr><td align="left">Number of positive nodes</td><td align="center">0.076</td><td align="center">1.079</td><td align="center">1.006~1.158</td><td align="left">0.034*</td></tr><tr><td align="left">Parametrial extension</td><td align="center">0.484</td><td align="center">1.623</td><td align="center">0.584~4.508</td><td align="left">0.353</td></tr><tr><td align="left">Vaginal margin involved</td><td align="center">-1.007</td><td align="center">0.365</td><td align="center">0.029~4.655</td><td align="left">0.438</td></tr><tr><td align="left">Depth of stromal invasion</td><td align="center">0.423</td><td align="center">1.526</td><td align="center">0.856~2.722</td><td align="left">0.152</td></tr><tr><td align="left">Lymphvascular permeation</td><td align="center">0.270</td><td align="center">1.311</td><td align="center">0.500~3.437</td><td align="left">0.582</td></tr><tr><td align="left">Nerve invasion</td><td align="center">0.101</td><td align="center">1.106</td><td align="center">0.092~13.337</td><td align="left">0.937</td></tr><tr><td align="left">Adjuvant therapy</td><td align="center">-1.684</td><td align="center">0.186</td><td align="center">0.075~0.459</td><td align="left">0.000*</td></tr></tbody></table><table-wrap-foot><p>* <italic>P </italic>&#x0003c; 0.05</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>Cervical cancer remains the third common cancer in women around the world, although its incidence is on the decline in North American and in Europe. It is estimated that there will be 10,370 new cases in 2005 in North America [<xref ref-type="bibr" rid="B8">8</xref>]. In many developing countries, not only is cervical cancer the most frequently occurring cancer among middle-aged women, but it is also a leading cause of death, partly due to the poor access to medical care and the unavailability of routine screening in many of these countries [<xref ref-type="bibr" rid="B9">9</xref>]. In Shanghai, the biggest city in China, there were 150 new cases in 2000. The standard incidence rate was 2.9 per 100 000 [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Radical surgery has been found to be very effective in patients with early stage (IB-IIA) cervical carcinoma [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. However, the 5-year survival has been lingering at 50%-90% during the past twenty years [<xref ref-type="bibr" rid="B14">14</xref>]. The reported risk factors of cervical carcinoma included clinical stage, bulky tumor, histological types, cellular differentiation, deep stromal invasion, parametrial extension, vaginal margin involved, lymphvascular permeation, lymph node metastasis, race and age [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. In most studies the presence of pelvic lymph node metastases has been associated with increased pelvic recurrence and distance metastases, and a decrease in overall survival. Our Cox proportional hazard model analysis showed cellular differentiation, number of positive nodes and adjuvant therapy to be the independent prognostic factors (<italic>P </italic>&#x0003c; 0.05). The 5-year survival of patients with one positive node (56.5%) was higher than that (36.4%) of those with two or more positive nodes (<italic>P </italic>&#x0003c; 0.05). There was no significant difference of pelvic recurrence between them. However, the former's distant metastases rate (5.9%) was lower than the latter's (32.7%) (<italic>P </italic>= 0.05). In the analysis of the site of lymph node metastases, the 5-year survival (33.3%) of the patients with positive common iliac node and paraaortic lymph node (PALN) was lower than that (43.1%) of patients with lower than common iliac node involvement. Unlike the series of Tsai the difference in our series was not statistically significant [<xref ref-type="bibr" rid="B19">19</xref>]. This is probably due to limited number of cases with paraaortic or common iliac nodes. The number of positive nodes correlated with the height of positive nodes (<italic>P </italic>&#x0003c; 0.01). The result suggested that in patients with more positive pelvic nodes there is higher chance of nodal metastasis at higher level node basins, which supported the external irradiation of PALN chain area for the multiple pelvic nodes involvement. The distant metastasis rate was 32.7% in patients with multiple positive lymph nodes, which showed the limitation of adjuvant radiotherapy and theoretically supported the postoperative combined chemotherapy.</p><p>The prognosis of patients with positive lymph node was poor because of local recurrence and distant metastasis. How to improve the prognosis of these patients has been the focus of gynecological oncology. Stock <italic>et al </italic>[<xref ref-type="bibr" rid="B7">7</xref>] compared postoperative whole pelvic irradiation with those treated with radical hysterectomy alone, and showed a significantly improved pelvic control rate, 5-year disease-free survival (DFS) and overall survival (OS) (78% Vs 45%, 65% Vs 41%, 58% Vs 46%, respectively).</p><p>Peters' study [<xref ref-type="bibr" rid="B20">20</xref>] demonstrated that postoperative radio-chemotherapy could greatly improve the 4-year DFS and OS compared to the adjuvant radiotherapy alone. In our study, adjuvant therapy improved the 5-year survival than the surgery alone (53.7% vs. 12.6%), decreased the pelvic recurrence and distant metastasis, which suggested the clinical importance of adjuvant therapy in patients with positive nodes. In this study the 5-year survival of adjuvant radio-chemotherapy arm was higher than adjuvant radiotherapy alone or chemotherapy alone. The pelvic recurrence (42.1%) and distant metastasis (31.6%) of the surgery alone were higher than the other three therapeutic arms. However, the differences were not significant and the limited number of cases in each arm could be the reason. It is necessary that these results are verified in prospective randomized control trials.</p><p>Several randomized clinical trials [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B25">25</xref>] performed by the Gynecologic Oncology Group (GOG), the Radiation Therapy Oncology Group (RTOG) and the Southwest Oncology Group (SWOG) have demonstrated a significant advantage both in DFS and OS when cisplatin-based chemotherapy was administered during radiation for advanced stages of cervical cancer and early stage disease with poor prognostic factors. Green <italic>et al </italic>[<xref ref-type="bibr" rid="B26">26</xref>] did a systemic review of all known randomized controlled trials published between 1981 and 2000, 2865&#x02013;3611 patients were available for analysis. The findings suggested that concomitant chemotherapy (CT) and radiotherapy (RT) improves OS and DFS, and reduces local and distant recurrence. Based on results, the US National Cancer Institute (NCI) released a clinical announcement supporting the concurrent use of cisplatin-based chemotherapy with RT for high-risk early stage and locally advanced stage cervical cancer [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. Recently a prospective randomized trial performed by the National Cancer Institute (NCI) of Canada [<xref ref-type="bibr" rid="B25">25</xref>] failed to show benefit with the use of chemoradiation compared with RT alone. The potential inclusion of paraaortic nodes positive patients and the significant difference in anemia raises question about this trial result [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>The therapy of patients with stage IIB cervical carcinoma is still a controversy [<xref ref-type="bibr" rid="B29">29</xref>]. Although radical radiotherapy (RT) is the proper choice for patients with stage IIB cervical cancer in general, the therapeutic effect is not as good as expected if the tumor is too bulky or is histologically adenocarcinoma. Hence a few gynecology oncologists tried brachytherapy and/or neoadjuvant chemotherapy to decrease the lesion, then performed radical surgery for some stage IIB patients with bulky tumor (&#x0003e;4 cm) or slight (less than 1/2) parametrial extension [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Postoperative adjuvant therapy would then be recommended according to risk factors [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. In our study, the 5-year survival of the patients with stage IIB cervical carcinoma was only 54.3%, which was not at all satisfactory compared with the reported 58.9%&#x02013;80.1% [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>]. So we advocate that radical surgery should be taken cautiously for this group of patients. Any attempt to improve their prognosis by means of adjuvant therapy is not recommended if the parametrium can not be thoroughly dissected from the pelvic wall.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors Contributions</title><p><bold>XC </bold>collected the data, patients' follow-up and drafted the article.</p><p><bold>SC, ZL, MT, MX </bold>collectively designed the study, participated in collection of data and revising the article.</p><p><bold>RZ </bold>participated in collection and analysis of data, revising the article</p></sec><sec><title>Funding Source</title><p>None</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Cha</surname><given-names>DS</given-names></name><name><surname>Walker</surname><given-names>JL</given-names></name><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Ramsinghani</surname><given-names>NS</given-names></name><name><surname>Manetta</surname><given-names>A</given-names></name><name><surname>Disaia</surname><given-names>PJ</given-names></name><name><surname>Berman</surname><given-names>ML</given-names></name></person-group><article-title>Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma</article-title><source>Gynecol Oncol</source><year>1994</year><volume>54</volume><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8020837</pub-id><pub-id pub-id-type="doi">10.1006/gyno.1994.1157</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>MP</given-names></name><name><surname>Morley</surname><given-names>GW</given-names></name></person-group><article-title>Stage Ib squamous cell cancer of the cervix: Clinicopathologic features related to survival</article-title><source>Am J Obstet Gynecol</source><year>1991</year><volume>164</volume><fpage>1520</fpage><lpage>1527</lpage><pub-id pub-id-type="pmid">2048598</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CT</given-names></name><name><surname>Cheng</surname><given-names>YS</given-names></name><name><surname>Su</surname><given-names>SC</given-names></name></person-group><article-title>Prognosis of uterine cervical cancer with extensive lymph node metastases: Special emphasis on the value of pelvic lymphadenectomy in the surgical treatment of uterine cervical cancer</article-title><source>Am J Obstet Gynecol</source><year>1972</year><volume>114</volume><fpage>954</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">4645136</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>K</given-names></name></person-group><article-title>The prognostic significance of number of positive nodes in cervical carcinoma stage Ib, IIa, IIb</article-title><source>Cancer</source><year>1990</year><volume>65</volume><fpage>1923</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">2372764</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanza</surname><given-names>A</given-names></name><name><surname>Re</surname><given-names>A</given-names></name><name><surname>Daddato</surname><given-names>F</given-names></name><name><surname>Raspollini</surname><given-names>M</given-names></name><name><surname>Proserpio</surname><given-names>D</given-names></name><name><surname>Bellino</surname><given-names>R</given-names></name><name><surname>Morino</surname><given-names>M</given-names></name><name><surname>Ferraris</surname><given-names>G</given-names></name></person-group><article-title>Treatment failure in cervical cancer: High risk features of relapse</article-title><source>Eur J Gynaecol Oncol</source><year>1989</year><volume>10</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">2806321</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pilleron</surname><given-names>JP</given-names></name><name><surname>Durand</surname><given-names>JC</given-names></name><name><surname>Hamelin</surname><given-names>JP</given-names></name></person-group><article-title>Prognostic value of node metastasis in cancer of the uterine cervix</article-title><source>Am J Obstet Gynecol</source><year>1974</year><volume>119</volume><fpage>458</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">4842590</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stock</surname><given-names>RG</given-names></name><name><surname>Chen</surname><given-names>AS</given-names></name><name><surname>Flickinger</surname><given-names>JC</given-names></name><name><surname>Kalnicki</surname><given-names>S</given-names></name><name><surname>Seski</surname><given-names>J</given-names></name></person-group><article-title>Node-positive cervical cancer: impact of pelvic irradiation and patterns of failure</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1995</year><volume>31</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">7995765</pub-id><pub-id pub-id-type="doi">10.1016/0360-3016(94)00391-W</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jamal</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Samuels</surname><given-names>A</given-names></name><name><surname>Tiwari</surname><given-names>RC</given-names></name><name><surname>Ghafoor</surname><given-names>A</given-names></name><name><surname>Fever</surname><given-names>EJ</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer Statistics, 2005</article-title><source>CA Cancer J Clin</source><year>2005</year><volume>55</volume><fpage>10</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15661684</pub-id></citation></ref><ref id="B9"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>DS</given-names></name><name><surname>Lanciano</surname><given-names>RM</given-names></name><name><surname>Kudelka</surname><given-names>AP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Pazdur R, Coia LR, Hoskins WJ, Wagman LD</surname></name></person-group><article-title>Cervical Cancer</article-title><source>In Cancer management: a multidisciplinary approach medical, surgical, radiation oncology</source><year>2001</year><edition>Fifth</edition><publisher-name>NY: PRR Inc</publisher-name><fpage>359</fpage><lpage>384</lpage></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><collab>Shanghai Institute of Cancer Research</collab></person-group><article-title>Morbidity of malignant tumors in Shanghai in 2000</article-title><source>Tumor</source><year>2003</year><volume>23</volume><fpage>532</fpage><comment>Chinese</comment></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamura</surname><given-names>T</given-names></name><name><surname>Tsukamoto</surname><given-names>N</given-names></name><name><surname>Tsuruchi</surname><given-names>N</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Matsuyama</surname><given-names>T</given-names></name><name><surname>Akazawa</surname><given-names>A</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name></person-group><article-title>Multivariate ananlysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy</article-title><source>Cancer</source><year>1992</year><volume>69</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">1727662</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>DS</given-names></name><name><surname>Gemignani</surname><given-names>MC</given-names></name><name><surname>Curtin</surname><given-names>JP</given-names></name><name><surname>Hoskins</surname><given-names>WJ</given-names></name></person-group><article-title>Long-term experience in the surgical management of cancer of the uterine cervix</article-title><source>Semin Surg Oncol</source><year>1999</year><volume>17</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">10504663</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-2388(199910/11)17:3&#x0003c;161::AID-SSU4&#x0003e;3.0.CO;2-I</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curtin</surname><given-names>JP</given-names></name><name><surname>Hoskins</surname><given-names>WJ</given-names></name><name><surname>Venkatraman</surname><given-names>ES</given-names></name><name><surname>Almadrones</surname><given-names>L</given-names></name><name><surname>Podratz</surname><given-names>KC</given-names></name><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Teneriello</surname><given-names>M</given-names></name><name><surname>Averette</surname><given-names>H</given-names></name><name><surname>Sevin</surname><given-names>BU</given-names></name></person-group><article-title>Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy(RH-PLND):A randomized phase III trial</article-title><source>Gynecol Oncol</source><year>1996</year><volume>61</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">8626113</pub-id><pub-id pub-id-type="doi">10.1006/gyno.1996.0087</pub-id></citation></ref><ref id="B14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Disaia</surname><given-names>PJ</given-names></name><name><surname>Creasman</surname><given-names>WT</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Disaia PJ, Creasman WT</surname></name></person-group><article-title>Invasive cervical cancer</article-title><source>Clinical Gynecologic Oncology</source><year>2002</year><edition>6</edition><publisher-name>Health Science Asia, Elsevier Science</publisher-name><fpage>71</fpage><lpage>111</lpage></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soisson</surname><given-names>AP</given-names></name><name><surname>Soper</surname><given-names>JT</given-names></name><name><surname>Clarke-Pearson</surname><given-names>DL</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Montana</surname><given-names>G</given-names></name><name><surname>Creasman</surname><given-names>WT</given-names></name></person-group><article-title>Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer</article-title><source>Gynecol Oncol</source><year>1990</year><volume>37</volume><fpage>390</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">2351324</pub-id><pub-id pub-id-type="doi">10.1016/0090-8258(90)90374-T</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Tsuneki</surname><given-names>I</given-names></name><name><surname>Aida</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name></person-group><article-title>High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation</article-title><source>Gynecol Oncol</source><year>2000</year><volume>77</volume><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">10785483</pub-id><pub-id pub-id-type="doi">10.1006/gyno.2000.5788</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwasaka</surname><given-names>T</given-names></name><name><surname>Kamura</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Matsuo</surname><given-names>N</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Sugimori</surname><given-names>H</given-names></name></person-group><article-title>Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: A comparison with effects of adjuvant radiotherapy</article-title><source>Obstet Gynecol</source><year>1998</year><volume>91</volume><fpage>977</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">9611008</pub-id><pub-id pub-id-type="doi">10.1016/S0029-7844(98)00079-9</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tattersall</surname><given-names>MH</given-names></name><name><surname>Ramirez</surname><given-names>C</given-names></name><name><surname>Coppleson</surname><given-names>M</given-names></name></person-group><article-title>A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage IB-IIA cervical cancer patients with pelvic lymph node metastases</article-title><source>Gynecol Oncol</source><year>1992</year><volume>46</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">1500019</pub-id><pub-id pub-id-type="doi">10.1016/0090-8258(92)90251-D</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CS</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Chang</surname><given-names>TC</given-names></name><name><surname>Tseng</surname><given-names>CJ</given-names></name><name><surname>Hong</surname><given-names>JH</given-names></name></person-group><article-title>The prognostic factors for patients with early cervical cancer treated by radical hysterrectomy and postoperative radiotherapy</article-title><source>Gynecol Oncol</source><year>1999</year><volume>75</volume><fpage>328</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">10600284</pub-id><pub-id pub-id-type="doi">10.1006/gyno.1999.5527</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>WA</given-names><suffix>3rd</suffix></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Barrett</surname><given-names>RJ</given-names><suffix>2nd</suffix></name><name><surname>Stock</surname><given-names>RJ</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Berek</surname><given-names>JS</given-names></name><name><surname>Souhami</surname><given-names>L</given-names></name><name><surname>Grigsby</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Alberts</surname><given-names>DS</given-names></name></person-group><article-title>Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>1606</fpage><lpage>1613</lpage><pub-id pub-id-type="pmid">10764420</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitney</surname><given-names>CW</given-names></name><name><surname>Sause</surname><given-names>W</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Malfetano</surname><given-names>JH</given-names></name><name><surname>Hannigan</surname><given-names>EV</given-names></name><name><surname>Fowler</surname><given-names>WC</given-names><suffix>Jr</suffix></name><name><surname>Clarke-Pearson</surname><given-names>DL</given-names></name><name><surname>Liao</surname><given-names>SY</given-names></name></person-group><article-title>Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1339</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">10334517</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>M</given-names></name><name><surname>Eifel</surname><given-names>PJ</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Grigsby</surname><given-names>PW</given-names></name><name><surname>Levenback</surname><given-names>C</given-names></name><name><surname>Stevens</surname><given-names>RE</given-names></name><name><surname>Rotman</surname><given-names>M</given-names></name><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Mutch</surname><given-names>DG</given-names></name></person-group><article-title>Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1137</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">10202164</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199904153401501</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>PG</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Watkins</surname><given-names>EB</given-names></name><name><surname>Thigpen</surname><given-names>T</given-names></name><name><surname>Deppe</surname><given-names>G</given-names></name><name><surname>Maiman</surname><given-names>MA</given-names></name><name><surname>Clarke-Pearson</surname><given-names>DL</given-names></name><name><surname>Insalaco</surname><given-names>S</given-names></name></person-group><article-title>Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1144</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">10202165</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199904153401502</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keys</surname><given-names>HM</given-names></name><name><surname>Bundy</surname><given-names>BM</given-names></name><name><surname>Stehman</surname><given-names>FB</given-names></name><name><surname>Muderspach</surname><given-names>LI</given-names></name><name><surname>Chafe</surname><given-names>WE</given-names></name><name><surname>Suggs</surname><given-names>CL</given-names><suffix>III</suffix></name><name><surname>Walker</surname><given-names>JL</given-names></name><name><surname>Gersell</surname><given-names>D</given-names></name></person-group><article-title>Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1154</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">10202166</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199904153401503</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pearcey</surname><given-names>R</given-names></name><name><surname>Brundage</surname><given-names>M</given-names></name><name><surname>Drouin</surname><given-names>P</given-names></name><name><surname>Jeffrey</surname><given-names>J</given-names></name><name><surname>Johnston</surname><given-names>D</given-names></name><name><surname>Lukka</surname><given-names>H</given-names></name><name><surname>Maclean</surname><given-names>G</given-names></name><name><surname>Souhami</surname><given-names>L</given-names></name><name><surname>Stuart</surname><given-names>G</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name></person-group><article-title>Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>966</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">11844818</pub-id><pub-id pub-id-type="doi">10.1200/JCO.20.4.966</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JA</given-names></name><name><surname>Kirwan</surname><given-names>JM</given-names></name><name><surname>Tierney</surname><given-names>JF</given-names></name><name><surname>Symonds</surname><given-names>P</given-names></name><name><surname>Fresco</surname><given-names>L</given-names></name><name><surname>Collingwood</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>CJ</given-names></name></person-group><article-title>Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and Meta-analysis</article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>781</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">11564482</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(01)05965-7</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>PG</given-names></name></person-group><article-title>Chemoradiotherapy for cervical cancer</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><fpage>270</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">11803143</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(01)00352-5</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loizzi</surname><given-names>V</given-names></name><name><surname>Cormio</surname><given-names>G</given-names></name><name><surname>Loverro</surname><given-names>G</given-names></name><name><surname>Selvaggi</surname><given-names>L</given-names></name><name><surname>Disaia</surname><given-names>PJ</given-names></name><name><surname>Cappuccini</surname><given-names>F</given-names></name></person-group><article-title>Chemoradiation: a new approach for the treatment of cervical cancer</article-title><source>Int J Gynecol Cancer</source><year>2003</year><volume>13</volume><fpage>580</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">14675339</pub-id><pub-id pub-id-type="doi">10.1046/j.1525-1438.2003.13378.x</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamura</surname><given-names>T</given-names></name><name><surname>Tsukamoto</surname><given-names>N</given-names></name><name><surname>Tsuruchi</surname><given-names>N</given-names></name><name><surname>Kaku</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>To</surname><given-names>N</given-names></name><name><surname>Akazawa</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name></person-group><article-title>Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection &#x02013; an analysis with mathematical statistics</article-title><source>Int J Gynecol Cancer</source><year>1993</year><volume>3</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">11578349</pub-id><pub-id pub-id-type="doi">10.1046/j.1525-1438.1993.03040219.x</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Hong</surname><given-names>JH</given-names></name><name><surname>Hsueh</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>KK</given-names></name><name><surname>Chang</surname><given-names>TC</given-names></name><name><surname>Tseng</surname><given-names>CJ</given-names></name><name><surname>Chou</surname><given-names>HH</given-names></name><name><surname>Huang</surname><given-names>KG</given-names></name></person-group><article-title>Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases</article-title><source>Cancer</source><year>1999</year><volume>85</volume><fpage>1537</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">10193944</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19990401)85:7&#x0003c;1537::AID-CNCR15&#x0003e;3.0.CO;2-6</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>watanabe</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Tsuneki</surname><given-names>I</given-names></name><name><surname>Aida</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name></person-group><article-title>High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation</article-title><source>Gynecol Oncol</source><year>2000</year><volume>77</volume><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">10785483</pub-id><pub-id pub-id-type="doi">10.1006/gyno.2000.5788</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Huang</surname><given-names>HJ</given-names></name><name><surname>Hong</surname><given-names>JH</given-names></name><name><surname>Chou</surname><given-names>HH</given-names></name><name><surname>Huang</surname><given-names>KG</given-names></name><name><surname>Lin</surname><given-names>JD</given-names></name></person-group><article-title>Recurrent cervical carcinoma after primary radical surgery</article-title><source>Am J Obstet Gynecol</source><year>1999</year><volume>181</volume><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">10486457</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Currie</surname><given-names>DW</given-names></name></person-group><article-title>Operative treatment of carcinoma of the cervix</article-title><source>J Obstet Gynaecol Br Commonw</source><year>1971</year><volume>78</volume><fpage>385</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">5558325</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>GH</given-names></name><name><surname>Rutledge</surname><given-names>FN</given-names></name></person-group><article-title>Extended field technique in the management of the cancers of the uterine cervix</article-title><source>Am J Roentgenol Radium Ther Nucl Med</source><year>1972</year><volume>114</volume><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">5061869</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pecorelli</surname><given-names>S</given-names></name></person-group><article-title>FIGO annual report on the results of treatment in gynaecological cancer</article-title><source>J Epidemiol Biostat</source><year>1998</year><volume>3</volume><fpage>5</fpage></citation></ref></ref-list></back></article>



